Davidal, One potential problem with CX-1739 for ADHD is it's shorter halflife -- 7.2 hours vrs 9-10 hours for CX-717 (and even with the longer halflife, they still used twice/day dosing in the CX-717 ADHD trial).
But CX-1739 is ~3X more potent than CX-717, so perhaps once/day dosing might be feasible, and once/day dosing may be the best way to minimize the insomnia side effect inherent in Ampakines. The backup compound CX-2076 has a longer halflife than CX-1739, so that might be better suited for once/day dosing in ADHD.
Market Data 
Markets 
AI
